Medical Affairs
Week ending August 30, 2026
1. Clinical accuracy snapshot
This week included 60 PI-type responses across 10 questions. Overall, answers generally covered the expected label themes—hypersensitivity, active infection, vaccination, infection risk, pediatric use, renal/hepatic impairment, and administration—but clinical consistency worsened: 29 inconsistency flags versus 26 last week, despite 20 fewer total responses.
The clearest label-accuracy concern is plaque-psoriasis dosing. Most answers state 300 mg subcutaneously weekly at Weeks 0–4, followed by every 4 weeks, but responses disagree on when maintenance begins: some say Week 5, others Week 8, and one says “Week 4/after.” This is a meaningful administration risk and should be corrected.
The boxed-warning question also produced a direct contradiction: five answer variants correctly state that Cosentyx has no U.S. boxed warning, while one states it “carries a boxed warning” for serious infection. This is a high-priority labeling discrepancy.
Monitoring answers may overstate requirements by describing TB testing, hepatitis screening, CBC/liver testing, or periodic laboratory monitoring as broadly “required.” The responses should distinguish label-based evaluation for infection and clinical monitoring from tests that may be risk- or practice-dependent. Active-infection answers were directionally consistent, but “do not start or continue” was sometimes stated too categorically rather than distinguishing clinical assessment and holding treatment for serious infection.
2. Off-label and substitution handling
Explicit off-label tagging fell to zero this week, compared with 3 last week. However, the boundary remains potentially blurry in brand answers that mention Cosentyx alongside Crohn’s disease/IBD without consistently clarifying approved indications versus disease areas where IL-17 inhibition may be clinically relevant but inappropriate or unapproved. This is particularly important because IBD was tagged in 32 answers overall.
Substitution answers correctly distinguish biologics from conventional small-molecule generics, e.g., “it generally isn’t substituted like a…‘generic.’” However, variants conflict by saying secukinumab biosimilars are “often available” versus describing them only as a possible alternative. Market availability, interchangeability, and pharmacy substitution are jurisdiction- and product-specific; these answers need current, sourced verification.
3. Unmet information needs
Recurring needs suitable for Medical Information or HCP content include:
- Exact regimen timing, including when maintenance begins after loading and how 150 mg devices are used.
- Pregnancy, breastfeeding, and infant live-vaccine guidance—the question explicitly asks about exposed infants, but answers incompletely address that issue.
- What screening is actually required before treatment versus optional/risk-based testing, especially TB, hepatitis, and routine laboratory monitoring.
- Active infection management: whether to delay initiation, hold a dose, or resume treatment after infection control.
- IL-17 inhibitor selection and switching, including onset, tolerability, IBD considerations, and insurance/prior authorization.
- Pharmacy substitution and biosimilar status, including who can authorize a switch and whether consent is required.
4. Change over time
Inconsistency flags have risen from 24 on August 16 and 26 last week to 29 this week, indicating a worsening consistency signal rather than improvement. Most category counts declined with lower response volume, but this is not evidence of better accuracy. Off-label discussion has fallen from 3 to 0; substitution tagging is steady at 11, suggesting a persistent information need. Competitor comparisons remain common, led by Humira (15), Stelara (14), Enbrel (14), and Taltz (14).
5. Recommended actions
- Immediately update the dosing standard response to eliminate Week 5/Week 8 discrepancies and align all variants with the current label.
- Create a boxed-warning versus important-warnings FAQ explicitly stating the U.S. label status and infection precautions.
- Develop a PI-grounded monitoring and infection-management response distinguishing required label precautions from clinician-dependent testing and treatment holds.
- Refresh pregnancy/lactation and infant-vaccine content, with specific label language and appropriate referral to the prescriber.
- Verify biosimilar/substitution information by market and add an approved-versus-off-label indication table for IBD-related questions.
These are clinical-content and accuracy issues; they should remain distinct from PV assessment of any safety signal.